Tagged with Fact

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Singapore Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for clinical gene therapy, discusses how his company is helping companies with mature preclinical gene therapy projects wanting to progress into the clinic. Moreover, he discusses why Singapore is…

China Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world, his talent strategy, and the use of AI within the sector.   BioDuro has very strong capabilities on the discovery…

Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Global Pharma industry insiders view vaccines as one of the most challenging products to manufacture, fundamentally due to the inherent biological variability of the pathogen itself, which is the starting block of any vaccine, as well as the resulting inherent variability of the biological raw materials and processes required in vaccine…

Switzerland Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up manufacturing capacity and scope, and why greater levels of both internal and external collaboration are crucial for the pharma industry…

Global Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating an inflection point in the ability to treat and potentially cure many intractable illnesses. To date, however, accessibility to many of these game changing technologies remains limited, often due to high upfront sticker-prices and…

Switzerland Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with biosimilar portfolios. Chief Commercial Officer Anil Okay, who sits in Switzerland, explains the four company traits that he believes will…

Switzerland The CEO & President of CDMO CordenPharma, Dr Michael Quirmbach, delves into the contract manufacturing industry, explaining the reasons behind the recent commercial success of his organization, including their partnership with Moderna, and his view on the new processes and technology shaping the industry.   A CDMO does not really…

Switzerland CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players also present in the biosimilars space.   We position ourselves as a pure play, differentiated, fully vertically integrated biosimilars development…

Switzerland Chief Financial Officer Marina Lugova introduces pharmaceutical company Synbias Pharma’s evolving European footprint, how the company has been able to withstand the COVID-19 pandemic and continue providing its essential products to customers, and its plans for the future, including further investments in the firm’s German production facility and new strategic…